Disappointing news 🙁
MedDay has just announced the second Phase III trial, SPI2, of high-dose biotin (MD1003) is negative. I am sure many people with progressive MS will be disappointed. However, this trial supports why we need to blinded, randomised, controlled trials; i.e. to test hypotheses. Let’s hope some lessons will be learnt from the trial data that will inform future trial design in more advanced MS.
I would like to thank all the people with progressive MS who participated in this study and all the diligent staff for making it happen. It may be a disappointing result, but without negative trial results, we don’t learn.
CoI: I am a member of SPI2 trial steering committee and our centre participated in the trial.